Certolizumab pegol in combination with dose-optimised methotrexate in DMARD-naïve patients with early, active rheumatoid arthritis with poor prognostic factors: 1-year results from C-EARLY, a randomised, double-blind, placebo-controlled phase III study

OBJECTIVES: To assess the efficacy and safety of certolizumab pegol (CZP)+dose-optimised methotrexate (MTX) versus placebo (PBO)+dose-optimised MTX in inducing and sustaining clinical remission in DMARD-naïve patients with moderate-to-severe, active, progressive rheumatoid arthritis (RA), with poor...

Descripción completa

Detalles Bibliográficos
Autores principales: Emery, P, Bingham, C O, Burmester, G R, Bykerk, V P, Furst, D E, Mariette, X, van der Heijde, D, van Vollenhoven, R, Arendt, C, Mountian, I, Purcaru, O, Tatla, D, VanLunen, B, Weinblatt, M E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2017
Materias:
Clinical and Epidemiological Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5264210/
https://www.ncbi.nlm.nih.gov/pubmed/27165179
http://dx.doi.org/10.1136/annrheumdis-2015-209057

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5264210/
https://www.ncbi.nlm.nih.gov/pubmed/27165179
http://dx.doi.org/10.1136/annrheumdis-2015-209057

Ejemplares similares